- Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants
- Preterm Infants and Nephrocalcinosis
- Randall’s Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
- Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature
- The Incidence and the Risk Factors of Nephrocalcinosis in Very Preterm Infants
Clinical Trials
- A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
- A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
- A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
- A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
- Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain
- Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
- Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I
- Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments
- Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1
- Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
- Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
- AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
- AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
- Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
- Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1
- Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
- Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
- Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation
- Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1
- Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
- Effect of Lamotrigine on Cognition in NF1
- Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1
- Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
- Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1
- Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
- Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
- Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
- Frameshift Peptides of Children With NF1
- From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1
- Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis
- Functional Imaging and Reading Deficit in Children With NF1
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem
- Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence
- Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial
- Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
- Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1
- Interventions for Reading Disabilities in NF1
- Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1
- Medical Treatment of “High-Risk” Neurofibromas
- Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
- MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
- MicroRNAs in Patients With Neurofibromatosis Type 1
- Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
- Modifying Genes in Neurofibromatosis 1
- Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients
- Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
- Natural History Study of Cutaneous Neurofibromas in People With NF1
- Neurobiology and Treatment of Reading Disability in NF-1
- Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia
- Neurofibromatosis Type 1 Brain Tumor Genetic Risk
- Neurofibromatosis Type 1 Patient Registry
- Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1
- NF-1, Nutraceutical Intervention
- NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate
- NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
- NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
- Non-invasive Stimulation in Neurofibromatosis Type 1
- Open Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1
- Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to
- Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Toxicity of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
- Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
- Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
- Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
- Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1
- Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
- Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
- Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
- Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation
- Quality of Friendships in Children With Neurofibromatosis
- R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
- Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
- Reading Disability in Children With NF1
- Reliability of Functional Outcome Measures in Neurofibromatosis 1
- Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
- Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
- Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)
- Stem Cells in NF1 Patients With Tumors of the Central Nervous System
- Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms
- Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
- Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
- Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
- Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
- Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients
- Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
- Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
- Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
- Treatment of NF1-related Plexiform Neurofibroma With Trametinib
- Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
- US Selumetinib Registry
- Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
- Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1
- Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children
- Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
- Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
- A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
- A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
- Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
- Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
- Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
- Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
- SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
- SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
- SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
- Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
- Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
- Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
- A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity
- A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients
- A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
- Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
- Acute Pain Caused by Paclitaxel in Patients With Cancer
- Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
- Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
- Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer
- Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
- Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
- Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
- Anakinra In Car-T Cell Mediated Neurotoxicity
- Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
- Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
- Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
- Brain Function in Children Previously Treated on Clinical Trials POG-9605 and POG-9201
- Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
- Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
- Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
- Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
- Cassava Intervention Project
- Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
- Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity
- Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
- Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
- Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
- D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain
- Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
- Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
- EEG Encephalopathy Patterns in Immune Effectors Cells-associated Neurotoxicity Syndrome (ICANS)Lay Language
- Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
- Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
- EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
- Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
- Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
- Envarsus Neurotoxicity Burden in Liver Transplant Patients
- Enzymatic Evaluation of General Anesthetic Induced Neurotoxicity in Patients With Aneurysmal Subarachnoid Hemorrhage
- Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy
- Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
- Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
- Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
- L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
- Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
- Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
- Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
- Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
- Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
- Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage
- Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients
- Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
- Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer
- Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors
- Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia
- Neurotoxicity Due to Chimeric Antigen Receptor-modified (CAR) T Cell Therapy
- Neurotoxicity Evaluation of bétalactamines in Intensive Care Unit and Identification of the Risk Factors
- PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
- Peri-Anesthetic Imaging of Cognitive Dysfunction
- Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases
- Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
- Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
- Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
- Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
- S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
- Scopolamine Treatment for Patients With Organophosphate Poisoning
- Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
- Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway
- Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation
- Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations
- To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity
- Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
- Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
- A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy
- An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops
- An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
- Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
- Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
- Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
- Corneal Nerves After Treatment With Cenegermin
- DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
- Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis
- Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
- Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
- Miniinvasive Corneal Neurotization. A Pilot Study.
- Nerve Growth Factor for the Treatment of Cornea Disease
- OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
- Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
- QST for Corneal Nerve Function
- REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
- Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis
- Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers
- Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
- Topical Insulin – Utility and Results in Neurotrophic Keratopathy Types 2 and 3
- Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.
- A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
- A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
- A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)
- Added Value of OCT for Diagnosing Recurrent BCC After Non-invasive Treatment
- An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer Participants
- An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
- Clinical Diagnosis of Basal Cell Carcinoma Subtype
- Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas
- Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma
- Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer
- Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
- Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
- Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
- Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma
- Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
- Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
- Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
- Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
- Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
- Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma
- To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
- Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
- Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.
- Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS
- Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma